particularly for people who have not yet received any treatment for their CLL. This type of therapy works by specifically targeting cancer cells and the underlying processes that lead to disease.

Research into immunotherapy against cancer typically focuses on better recognition of cancer cells by the body's own immune ...

A study in Cancer compared the accuracy of five risk scores for time to treatment in CLL, including the IPS-E, CR0, AIPS-E, ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells ...

SUV remains the most widely used PET parameter to evaluate NHLs because it is directly associated with lymphoma aggressiveness.

Researchers uncover how leukemia drains T cells' energy, paving the way for stronger cancer immunotherapy and enhancing CAR T ...

Research into immunotherapy against cancer typically focuses on better recognition of cancer cells by the body's own immune system. Researchers at Amsterdam UMC and Moffitt Cancer Center have taken a ...

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found ...

The only difference between each cancer is its location in the body. CLL occurs when the cancer cells are found in the blood, while SLL occurs when they are found in the lymph nodes. CLL can ...

When Jennifer Woyach, MD, started as a resident and fellow two decades ago, patients with chronic lymphocytic leukemia (CLL) ...

The following is a summary of "BCL-2 dependence is a favorable predictive marker of response to therapy for chronic ...

Immunotherapy research primarily focuses on improving the body’s immune system’s recognition of cancer cells. However, ...